Antibody charge variant modulation by in vitro enzymatic treatment in different Chinese hamster ovary cell cultures
Модуляция вариантов заряда антител с помощью ферментативной обработки in vitro в различных культурах клеток китайского хомячка
2022-05-10
SCID: 54.1/zevwpzvy
Discuss with AI
C-terminal lysine removalChinese hamster ovary cell culturescarboxypeptidase Bcharge variant modulationmonoclonal antibodies
Figures from the paper
Abstract (AI)
Charge variants represent a critical quality attribute that must be controlled during the development and manufacturing of monoclonal antibodies (mAb). Previously, we reported the development of a cost-effective enzymatic treatment capable of removing the C-terminal lysine from a mAb produced by a Chinese hamster ovary (CHO) GS cell line. This treatment resulted in a significant decrease in basic charge variants and a corresponding improvement in the main peak, enabling a longer cell culture production duration for titer improvement. Here, we describe this enzymatic treatment protocol in detail and demonstrate its applicability to two additional mAbs produced by distinct industrial cell lines. The simple addition of carboxypeptidase B (CpB) at a ratio of 1:10,000 (w/w) to whole cell cultures significantly improved the main peaks for both mAbs without affecting other critical quality attributes, including size exclusion chromatography impurities and N-glycans. Our results demonstrate that this in vitro CpB treatment protocol can be used as a platform strategy to improve main peak for mAbs that exhibit high levels of basic variants attributable to C-terminal lysines. An in vitro enzymatic treatment in general may be another good addition to existing in vivo CHO cell culture strategies for titer improvement and control of critical quality attributes.
Key Findings
1
A cost-effective in vitro carboxypeptidase B (CpB) treatment removes monoclonal antibody C-terminal lysines and reduces basic charge variants.
2
Adding CpB to whole CHO cell cultures at a 1:10,000 (w/w) ratio significantly improved the main peak for two additional mAbs from distinct industrial cell lines.
3
The CpB treatment improved charge-variant profiles without affecting size-exclusion chromatography impurities or N-glycan critical quality attributes.
4
The protocol provides a platform strategy for mAbs with high basic-variant levels caused by C-terminal lysines and may extend culture duration for titer improvement.
Research Object
Monoclonal antibodies produced in Chinese hamster ovary (CHO) cell cultures, including mAbs with C-terminal lysine–associated basic charge variants
Research Subject
The effects of in vitro carboxypeptidase B treatment on antibody charge-variant profiles, main-peak improvement, and other critical quality attributes
Publication Details
Publication Date
2022-05-10
Journal
Publisher
ISSN
Cited by
3
Access Type
Author Information
Download PDF
Subscribe to digest